It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Here, a comparative toxicity assessment of precursor carbon dots from coffee waste (cofCDs) obtained using green chemistry principles and Gd-doped nanohybrids (cofNHs) was performed using hematological, biochemical, histopathological assays in vivo (CD1 mice, intraperitoneal administration, 14 days), and neurochemical approach in vitro (rat cortex nerve terminals, synaptosomes). Serum biochemistry data revealed similar changes in cofCDs and cofNHs-treated groups, i.e. no changes in liver enzymes' activities and creatinine, but decreased urea and total protein values. Hematology data demonstrated increased lymphocytes and concomitantly decreased granulocytes in both groups, which could evidence inflammatory processes in the organism and was confirmed by liver histopathology; decreased red blood cell-associated parameters and platelet count, and increased mean platelet volume, which might indicate concerns with platelet maturation and was confirmed by spleen histopathology. So, relative safety of both cofCDs and cofNHs for kidney, liver and spleen was shown, whereas there were concerns about platelet maturation and erythropoiesis. In acute neurotoxicity study, cofCDs and cofNHs (0.01 mg/ml) did not affect the extracellular level of L-[14C]glutamate and [3H]GABA in nerve terminal preparations. Therefore, cofNHs demonstrated minimal changes in serum biochemistry and hematology assays, had no acute neurotoxicity signs, and can be considered as perspective biocompatible non-toxic theragnostic agent.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Taras Shevchenko University of Kyiv, Corporation Science Park, Kyiv, Ukraine (GRID:grid.34555.32) (ISNI:0000 0004 0385 8248); Taras Shevchenko National University of Kyiv, Institute of High Technologies, Kyiv, Ukraine (GRID:grid.34555.32) (ISNI:0000 0004 0385 8248)
2 Taras Shevchenko University of Kyiv, Corporation Science Park, Kyiv, Ukraine (GRID:grid.34555.32) (ISNI:0000 0004 0385 8248); Palladin Institute of Biochemistry National Academy of Sciences of Ukraine, Kyiv, Ukraine (GRID:grid.419966.5) (ISNI:0000 0004 0497 5200)
3 Palladin Institute of Biochemistry National Academy of Sciences of Ukraine, Kyiv, Ukraine (GRID:grid.419966.5) (ISNI:0000 0004 0497 5200)
4 UMR-5306, Claude Bernard University of Lyon/CNRS, Université de Lyon, Light Matter Institute, Villeurbanne Cedex, France (GRID:grid.7849.2) (ISNI:0000 0001 2150 7757)